A multidisciplinary committee of international experts have released a new clinical practice guideline on the diagnosis of adult hypersensitivity pneumonitis, an immune-mediated inflammatory lung and small airway disease.
Although the overall rheumatoid arthritis-related mortality rates have been decreasing in recent years, rates of mortality among patients with rheumatoid arthritis-associated interstitial lung disease remain stable.
As a central goal of PF Awareness Month and their ongoing work, the Pulmonary Fibrosis Foundation aims to improve diagnostic delays and misdiagnoses in this patient population.
Individuals with pulmonary fibrosis could develop more serious complications if infected with COVID-19, and those awaiting organ transplantation and other surgical interventions may face delays because of the pandemic.
The Fairfax idiopathic pulmonary fibrosis (IPF) clinical score was an accurate tool for estimating probability of IPF in patients with interstitial lung disease.
Greater pericardial adipose tissue and abdominal visceral adipose tissue has been linked to interstitial lung abnormalities, increased high attenuation areas, and decreased forced vital capacity.
Early identification if interstitial lung disease (ILD), followed by subsequent tocilizumab therapy initiation, may preserve lung function in patients with systemic sclerosis-associated ILD.
In patients with fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis, adding pirfenidone to treatment may attenuate disease progression.
There were no limiting safety or tolerability signals identified with the addition of valganciclovir to pirfenidone therapy in patients with idiopathic pulmonary fibrosis.
Lower percent predicted forced vital capacity may serve as an independent predictive factor for adverse outcomes in patients with interstitial lung disease and microscopic polyangiitis.
A self-reported family history of pulmonary fibrosis (PF) is predictive of decreased transplant-free survival in patients with idiopathic PF (IPF) and in those with non-IPF interstitial lung disease.
